Structured Data Objects
Sections
Section fields
id
: Unique section identifier (e.g., "s1", "s2a")level
: Hierarchy depth (1 = main, 2 = subsection, etc.)order
: Display order within the documenttitle
: Original section titleanchor
: URL-safe identifiercategory
: Semantic category (introduction, methods, results, discussion, etc.)path_anchor
: Full hierarchical pathpath_anchors
: Array of parent section anchorsnormalized_title
: Cleaned titletop_normalized_title
: Top-level section title
{
"public_id":"1642632597.v1",
"open_access":true,
"normalized":true,
"updated_at":"2025-10-12T20:44:54.501Z",
"data":{
"sections":[
{
"id":"s2",
"level":1,
"order":1,
"title":"METHODS",
"anchor":"methods",
"category":"methods",
"path_anchor":"methods",
"normalized_title":"Methods",
"top_normalized_title":"Methods"
},
{
"id":"s2a",
"level":2,
"order":2,
"title":"Dosimetry",
"anchor":"dosimetry",
"category":"methods",
"path_anchor":"methods/dosimetry",
"path_anchors":[
"methods"
],
"normalized_title":"Methods",
"top_normalized_title":"Methods"
}
]
}
}
Assets
{
"public_id":"1642632597.v1",
"open_access":true,
"normalized":true,
"updated_at":"2025-10-12T20:44:54.501Z",
"data":{
"assets":{
"tables":[
{
"id":"tbl1",
"hash":"sha256:abc123def456789...",
"label":"Table 1.",
"title":Patient demographics and baseline characteristics",
"caption_text":"Patient and lesion characteristics as previously reported (7)"
},
],
"figures":[
{
"id":"fig1",
"hash":"sha256:def456abc789123...",
"label":"Figure 1.",
"caption_text":"Study flow diagram showing patient enrollment"
}
]
}
}
}
Blocks
Block fields
kind
: Content type (paragraph, list, equation, etc.)order
: Document orderraw_xml
: Original XML from the source documentblock_id
: Unique block identifierpath_anchor
: Hierarchical path within the documentindex_in_section
: Position within the parent sectionxrefs
: Array of cross-references (optional)plain_text
: Plain text contentsection_id
: Parent section identifierminimal_xml
: Simplified XML with essential formatting
Cross-reference fields (when present)
span
: Character range [start, end] in plain texttype
: Reference type (citation, table-ref, figure-ref, extlink, etc.)label
: Display labeltarget_id
: Target identifier
{
"public_id":"ver:medrxiv:2025.08.07.25333034:v1",
"open_access":true,
"normalized":true,
"updated_at":"2025-01-15T10:30:00.000Z",
"data":{
"blocks":[
{
"kind":"paragraph",
"order":1,
"block_id":"b2103236719886133",
"section_id":"s2a",
"path_anchor":"methods/dosimetry",
"index_in_section":4,
"xrefs":[
{
"span":[143, 154],
"type":"extlink",
"label":"NCT05413850",
"target_id":"NCT05413850"
},
{
"span":[266, 267],
"type":"citation",
"label":"7",
"target_id":"c7"
},
{
"span":[303, 310],
"type":"table-ref",
"label":"Table 1",
"target_id":"tbl1"
}
],
"raw_xml":"<p hwp:id=\"p-25\">Using dosimetry data from a Phase 1 trial of novel RLT,<sup>177</sup>Lu-rhPSMA-10.1, in 13 patients with metastatic castration-resistant prostate cancer [<ext-link l:rel=\"related\" l:ref-type=\"CLINTRIALGOV\" l:ref=\"NCT05413850\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT05413850\" hwp:id=\"ext-link-3\">NCT05413850</ext-link>], time–activity curves were generated for the first treatment cycle (Cycle 1) for each of the 13 participants (<italic toggle=\"yes\"><xref ref-type=\"bibr\" rid=\"c7\" hwp:id=\"xref-ref-7-1\" hwp:rel-id=\"ref-7\">7</xref></italic>). Patient details are described in<xref rid=\"tbl1\" ref-type=\"table\" hwp:id=\"xref-table-wrap-1-1\" hwp:rel-id=\"T1\">Table 1</xref>.</p>",
"plain_text":"Using dosimetry data from a Phase 1 trial of novel RLT,177Lu-rhPSMA-10.1, in 13 patients with metastatic castration-resistant prostate cancer [NCT05413850], time–activity curves were generated for the first treatment cycle (Cycle 1) for each of the 13 participants (7). Patient details are described in Table",
"minimal_xml":"<p hwp:id=\"p-25\">Using dosimetry data from a Phase 1 trial of novel RLT,<sup>177</sup>Lu-rhPSMA-10.1, in 13 patients with metastatic castration-resistant prostate cancer [<extlink href=\"NCT05413850\">NCT05413850</extlink>], time–activity curves were generated for the first treatment cycle (Cycle 1) for each of the 13 participants (<bibliography target=\"c7\">7</bibliography>). Patient details are described in <table target=\"tbl1\">Table 1</table>.</p>",
}
]
}
}
Citations
{
"public_id":"1642632597.v1",
"open_access":true,
"normalized":true,
"updated_at":"2025-10-12T20:44:54.501Z",
"data":{
"citations":[
{
"id":"c1",
"label":"1",
"raw":"Kratochwil C. , Bruchertseifer F. , Giesel FL. 225Ac–PSMA–617 for PSMA–targeted α–radiation therapy of metastatic castration–resistant prostate cancer. J Nucl Med. 57 (12) 1941–1944 (2016).",
"xml":"<citation publication-type=\"journal\" citation-type=\"journal\" ref:id=\"2025.08.08.25333110v1.1\" ref:linkable=\"yes\" ref:use-reference-as-is=\"yes\" hwp:id=\"citation-1\"><string-name name-style=\"western\" hwp:sortable=\"Kratochwil C\"><surname>Kratochwil</surname><given-names>C</given-names></string-name>,<string-name name-style=\"western\" hwp:sortable=\"Bruchertseifer F\"><surname>Bruchertseifer</surname><given-names>F</given-names></string-name>,<string-name name-style=\"western\" hwp:sortable=\"Giesel FL\"><surname>Giesel</surname><given-names>FL</given-names></string-name>,<etal>et al.</etal><article-title hwp:id=\"article-title-2\">225Ac-PSMA-617 for PSMA-targeted α-radiation therapy of metastatic castration-resistant prostate cancer</article-title>.<source hwp:id=\"source-1\">J Nucl Med</source>.<year>2016</year>;<volume>57</volume>(<issue>12</issue>):<fpage>1941</fpage>–<lpage>1944</lpage>.</citation>",
"xml_minimal":"<citation><string-name><surname>Kratochwil</surname><given-names>C</given-names></string-name>,<string-name><surname>Bruchertseifer</surname><given-names>F</given-names></string-name>,<string-name><surname>Giesel</surname><given-names>FL</given-names></string-name>,<etal>et al.</etal><article-title>225Ac-PSMA-617 for PSMA-targeted α-radiation therapy of metastatic castration-resistant prostate cancer</article-title>.<source>J Nucl Med</source>.<year>2016</year>;<volume>57</volume>(<issue>12</issue>):<fpage>1941</fpage>–<lpage>1944</lpage>.</citation>"
"text":"Kratochwil C , Bruchertseifer F , Giesel FL , et al. 225Ac-PSMA-617 for PSMA-targeted α-radiation therapy of metastatic castration-resistant prostate cancer . J Nucl Med . 2016 ; 57 ( 12 ): 1941 – 1944 .",
}
]
}
}
Last updated